EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region

Primoz Strojan, Tanja Jesenko, Masa Omerzel, Crt Jamsek, Ales Groselj, Ursa Lampreht Tratar, Bostjan Markelc, Gorana Gasljevic, Alojz Ihan, Frenk Smrekar, Matjaz Peterka, Maja Cemazar und 1 weitere

European Journal of Surgical Oncology · 2025

DOI: 10.1016/j.ejso.2025.109574 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Primoz Strojan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Plasmids, Genetic Therapy, Basal Cell Carcinoma, Electroporation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Republic of Slovenia Ministry of Education Science and Sport, European Regional Development Fund, Slovenian Research and Innovation Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In the treatment of cancer, immunomodulatory approaches are developed to support the organism in fighting cancer or to enhance the immunomodulatory effects of local ablative techniques. To this end, we conducted an interventional, open-label, single-arm Phase I trial to evaluate the safety and tolerability of intratumoral phIL12 plasmid DNA gene electrotransfer as primary objectives. METHODS: The study was dose-escalating with 3 consecutive cohorts of 3 patients per phIL12 dose level (0.5 mg/ml, 1 mg/ml or 2 mg/ml) according to a matched 3 + 3 design. Recruitment of patients was staggered. The waiting period was 30 days after treatment of the previous patient, based on the expected duration of acute and subacute toxicity. RESULTS: The results of this phase I clinical trial in basal cell carcinoma demonstrated the feasibility and safety of the phIL12 plasmid by gene electrotransfer. We were able to demonstrate that phIL12 gene electrotransfer induced local IL-12 production, which was accompanied with IFN-γ expression. Triggering of the immune response was demonstrated by increased infiltration of immune cells and some antitumor effect. Based on these data, we would recommend the use of a concentration of 2 mg/ml of the plasmid in future trials. CONCLUSION: The trial lays the foundation for future Phase II clinical trials in which phIL12 gene electrotransfer is used in combination with local tumor-ablative approaches, such as electrochemotherapy or radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PlasmidsGenetic TherapyBasal Cell CarcinomaElectroporationHead and Neck NeoplasmsGene Transfer TechniquesSkin NeoplasmsHumansMaleFemaleMiddle AgedAgedInterleukin-12Interferon-gammaTreatment Outcome

Stichwörter der Autor:innen

Basal cell carcinomaGene electrotransferInterleukin-12Phase I clinical trialphIL12 plasmid

Substanzen

Interleukin-12Interferon-gamma

Autor:innen und Institutionen

  • Institute of Oncology Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Slovenia.
  • Institute of Oncology Ljubljana, Slovenia; Faculty of Health Sciences, University of Ljubljana, Slovenia.
  • Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Slovenia.
  • Institute of Oncology Ljubljana, Slovenia; Veterinary Faculty, University of Ljubljana, Slovenia.
  • Institute of Oncology Ljubljana, Slovenia; Biotechnical Faculty, University of Ljubljana, Slovenia.
  • Institute of Oncology Ljubljana, Slovenia; Medical Faculty, University of Maribor, Slovenia.

Förderung

  • Republic of Slovenia Ministry of Education Science and Sport
  • European Regional Development Fund
  • Slovenian Research and Innovation Agency

Zitieren

APA

Strojan, P., Jesenko, T., Omerzel, M., Jamsek, C., Groselj, A., Tratar, U. L., Markelc, B., Gasljevic, G., Ihan, A., Smrekar, F., Peterka, M., Cemazar, M., & Sersa, G. (2025). Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2025.109574

Vancouver

Strojan P, Jesenko T, Omerzel M, Jamsek C, Groselj A, Tratar UL, et al. Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2025.109574

BibTeX
@article{Strojan2025,
  author = {Strojan, Primoz and Jesenko, Tanja and Omerzel, Masa and Jamsek, Crt and Groselj, Ales and Tratar, Ursa Lampreht and Markelc, Bostjan and Gasljevic, Gorana and Ihan, Alojz and Smrekar, Frenk and Peterka, Matjaz and Cemazar, Maja and Sersa, Gregor},
  title = {Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region},
  journal = {European Journal of Surgical Oncology},
  year = {2025},
  doi = {10.1016/j.ejso.2025.109574}
}
Kostenlos starten →